Abbott Opposes Proposed MDL for Spinal Cord Stimulator Injury Actions
Abbott Laboratories opposed a proposed multidistrict litigation (MDL) to centralize lawsuits claiming injuries from its spinal cord stimulators (SCSs). In an Aug. 4 filing to the Judicial Panel on Multidistrict Litigation, Abbott said the cases involve individualized facts and that an MDL would be overbroad and delay resolutions, according to the filing.
How this was made
The 30-second read
Why it matters
Abbott’s opposition frames the MDL as inefficient due to individualized, plaintiff-specific factual issues, and suggests it would delay resolution of what it characterizes as frivolous cases.
Market read
This is a procedural litigation development for ABT, but it does not report a ruling, settlement, or new damages evidence.
What to watch
The article does not state whether the panel has ruled on the MDL request, nor does it quantify claims, settlement posture, or any new evidence of causation.
Background
Plaintiffs Ray Lavigne and Renee Moss sought centralization of spinal cord stimulator injury cases into a multidistrict litigation (MDL) proceeding.
Ticker impact
Abbott opposes an MDL to centralize spinal cord stimulator injury lawsuits, arguing individualized facts make centralization overbroad and delay resolution.
Near-term impact likely limited, but it can influence perceived litigation efficiency and uncertainty around SCS injury exposure.
The article describes Abbott’s opposition arguments to the MDL panel, not a settlement, damages finding, or new liability determination. MDL outcomes can still shift procedural risk and duration, which may modestly affect sentiment.
Market effects
Could be a read-through for other medical device makers facing mass-tort MDL attempts, highlighting arguments about individualized injury causation.
Primarily US litigation process, with limited direct regional market spillover.
Low, as the dispute is US federal procedural and product-specific.
Counterpoint
Even if Abbott’s opposition is rejected, the MDL may still reduce costs and improve coordination, potentially lowering long-run litigation uncertainty.
Key entities
- companyAbbott Laboratories
Opposed the proposed MDL for spinal cord stimulator injury actions, arguing individualized issues make centralization overbroad and unwieldy.
- US court bodyJudicial Panel on Multidistrict Litigation
Receives the opposition filing and decides whether to centralize the cases into an MDL.
- plaintiffsRay Lavigne and Renee Moss
Movants seeking MDL centralization of the spinal cord stimulator injury lawsuits.
